Phaseline

Companies › Anxo Pharmaceutical

Anxo Pharmaceutical: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Psychiatry; next expected readout Jul 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
AX251 LAI
Dopamine D2/D3 receptor partial agonist
DRD2, DRD3Phase 1SchizophreniaJul 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07484204AX251 LAIPhase 1SchizophreniaPsychiatryJul 2028

Targets

DRD2 (1) DRD3 (1)

Companies with the same targets

LB Pharmaceuticals Gedeon Richter Serina Therapeutics Boryung Pharmaceutical Mapi Pharma AbbVie MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals Prilenia Changchun GeneScience Pharmaceutical Vanda Pharmaceuticals

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.